{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:44:57Z","timestamp":1792118697836,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.psc.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:38:10Z","timestamp":1718206690000},"page":"689-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacotherapy for Anxiety Disorders"],"prefix":"10.1016","volume":"47","author":[{"given":"Kerry B.","family":"O\u2019Leary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.psc.2024.04.012_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/da.22728","article-title":"Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Carpenter","year":"2018","journal-title":"Depress Anxiety"},{"issue":"9","key":"10.1016\/j.psc.2024.04.012_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2024.04.012_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2018.03.002","article-title":"Remission in CBT for adult anxiety disorders: A meta-analysis","volume":"61","author":"Springer","year":"2018","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2215-0366(14)70329-3","article-title":"Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis","volume":"1","author":"Mayo-Wilson","year":"2014","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.psc.2024.04.012_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2019.08.009","article-title":"Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis","volume":"118","author":"He","year":"2019","journal-title":"J\u00a0Psychiatr Res"},{"issue":"10173","key":"10.1016\/j.psc.2024.04.012_bib9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis [published correction appears in Lancet. 2019 Apr 27;393(10182):1698]","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2024.04.012_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpsychires.2019.08.014","article-title":"Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis","volume":"118","author":"Chen","year":"2019","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.psc.2024.04.012_bib11","doi-asserted-by":"crossref","first-page":"580858","DOI":"10.3389\/fphar.2020.580858","article-title":"Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials","volume":"11","author":"Kong","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40273-013-0031-z","article-title":"The cost effectiveness of pharmacological treatments for generalized anxiety disorder","volume":"31","author":"Mavranezouli","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hup.1019","article-title":"How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database","volume":"24","author":"Baldwin","year":"2009","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"10.1016\/j.psc.2024.04.012_bib14","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1017\/S0033291723001630","volume":"53","author":"Gosmann","year":"2023","journal-title":"Psychol Med"},{"issue":"12","key":"10.1016\/j.psc.2024.04.012_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.4088\/JCP.09r05786blu","article-title":"Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms","volume":"71","author":"Andrade","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib17","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis","volume":"159","author":"Trindade","year":"1998","journal-title":"CMAJ (Can Med Assoc J)"},{"key":"10.1016\/j.psc.2024.04.012_bib18","series-title":"StatPearls","article-title":"Tricyclic antidepressant toxicity","author":"Khalid","year":"2023"},{"issue":"11","key":"10.1016\/j.psc.2024.04.012_bib19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"Rickels","year":"1993","journal-title":"Arch Gen Psychiatr"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0447.1997.tb09660.x","article-title":"Paroxetine efficacy in the treatment of generalized anxiety disorder","volume":"95","author":"Rocca","year":"1997","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib21","first-page":"46","article-title":"A\u00a0pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder","volume":"41","author":"Bystritsky","year":"2008","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/JCP.0000000000001658","article-title":"Does bupropion increase anxiety?: a naturalistic study over 12\u00a0weeks","volume":"43","author":"Poliacoff","year":"2023","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib23","first-page":"36","article-title":"Vortioxetine (brintellix): a new serotonergic antidepressant","volume":"40","author":"D'Agostino","year":"2015","journal-title":"P\u00a0T"},{"key":"10.1016\/j.psc.2024.04.012_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis","volume":"64","author":"Pae","year":"2015","journal-title":"J\u00a0Psychiatr Res"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib25","first-page":"2036","article-title":"Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing ssri-induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J\u00a0Sex Med"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2045125311409486","article-title":"Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor","volume":"1","author":"Schwartz","year":"2011","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.psc.2024.04.012_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajp.2017.01.016","article-title":"Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis","volume":"26","author":"Zareifopoulos","year":"2017","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.psc.2024.04.012_bib28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/NDT.S103408","article-title":"Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies","volume":"12","author":"Clayton","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib29","first-page":"CD006115","article-title":"Azapirones for generalized anxiety disorder","volume":"2006","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib30","first-page":"956","article-title":"The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature","volume":"8","author":"Moll","year":"2011","journal-title":"J\u00a0Sex Med"},{"issue":"8","key":"10.1016\/j.psc.2024.04.012_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.psc.2024.04.012_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-981-32-9705-0_20","article-title":"Role of benzodiazepines in anxiety disorders","volume":"1191","author":"Balon","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: a meta-analysis","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/psyg.12239","article-title":"Association between high cumulative dose of benzodiazepine in chinese patients and risk of dementia: a preliminary retrospective case-control study","volume":"17","author":"Chan","year":"2017","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.psc.2024.04.012_bib35","series-title":"Generalised anxiety disorder in adults: management in primary, secondary and community care","year":"2011"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.psc.2024.04.012_bib38","first-page":"6045017","article-title":"Treatment of generalized anxiety disorder with gabapentin","volume":"2017","author":"Markota","year":"2017","journal-title":"Case Rep Psychiatry"},{"key":"10.1016\/j.psc.2024.04.012_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/DDDT.S89485","article-title":"Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Maneeton","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"10.1016\/j.psc.2024.04.012_bib40","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis [published correction appears in JAMA. 2012 Jan 11;307(2):147]","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2024.04.012_bib41","first-page":"CD006815","article-title":"Hydroxyzine for generalised anxiety disorder","volume":"12","author":"Guaiana","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2024.04.012_bib42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatr"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib43","first-page":"145","article-title":"Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance","volume":"19","author":"Melaragno","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"10.1016\/j.psc.2024.04.012_bib44","series-title":"Psychiatry in primary care","article-title":"The adult patient with an anxiety disorder","author":"Brotea","year":"2019"},{"issue":"11","key":"10.1016\/j.psc.2024.04.012_bib45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1755-5949.2008.00076.x","article-title":"Open-label support for duloxetine for the treatment of panic disorder","volume":"15","author":"Simon","year":"2009","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib48","first-page":"CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1600-0447.2002.02255.x","article-title":"SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis","volume":"106","author":"Bakker","year":"2002","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib50","first-page":"55","article-title":"Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks","volume":"48","author":"Buigues","year":"1987","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.psychres.2008.06.025","article-title":"Double-blind comparison of 30 and 60\u00a0mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder","volume":"175","author":"Nardi","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.psc.2024.04.012_bib52","series-title":"StatPearls","article-title":"MAO Inhibitors","author":"Sabri","year":"2023"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00004850-200111000-00008","article-title":"The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period","volume":"16","author":"Boshuisen","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib54","first-page":"35","article-title":"Mirtazapine in the treatment of panic disorder: an open-label trial","volume":"18","author":"Sarchiapone","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib55","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro","year":"2001","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.psc.2024.04.012_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12991-018-0190-6","article-title":"An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder","volume":"17","author":"Shah","year":"2018","journal-title":"Ann Gen Psychiatr"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder","volume":"20","author":"Pande","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib59","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/npr2.12275","article-title":"Antidepressants for social anxiety disorder: A systematic review and meta-analysis","volume":"42","author":"Mitsui","year":"2022","journal-title":"Neuropsychopharmacol Rep"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14656566.2017.1285907","article-title":"A\u00a0meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators","volume":"18","author":"Curtiss","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib61","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo","volume":"13","author":"Davidson","year":"1993","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib62","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","article-title":"Cognitive-behavioral and pharmacological treatments of social phobia. a controlled study","volume":"48","author":"Gelernter","year":"1991","journal-title":"Arch Gen Psychiatr"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib63","first-page":"CD001206","article-title":"Pharmacotherapy for social anxiety disorder (SAnD)","volume":"10","author":"Williams","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/13543784.2014.979283","article-title":"Pregabalin for the treatment of social anxiety disorder","volume":"24","author":"Kawalec","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib66","article-title":"A\u00a012-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder","volume":"17","author":"Careri","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"issue":"12","key":"10.1016\/j.psc.2024.04.012_bib67","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/da.22702","article-title":"Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder","volume":"34","author":"Liebowitz","year":"2017","journal-title":"Depress Anxiety"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib68","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/01.jcp.0000186871.04984.8d","article-title":"Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Muehlbacher","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib69","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/YIC.0b013e32833a4d71","article-title":"Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Schutters","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","article-title":"Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study","volume":"58","author":"van Vliet","year":"1997","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-0327(96)00030-4","article-title":"Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia","volume":"39","author":"Van Ameringen","year":"1996","journal-title":"J\u00a0Affect Disord"},{"issue":"7","key":"10.1016\/j.psc.2024.04.012_bib72","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","article-title":"Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study","volume":"31","author":"Vaishnavi","year":"2007","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.chc.2023.02.006","article-title":"Advances in pharmacotherapy for pediatric anxiety disorders","volume":"32","author":"Nicotra","year":"2023","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/da.22329","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"32","author":"Strawn","year":"2015","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib75","doi-asserted-by":"crossref","first-page":"17r12064","DOI":"10.4088\/JCP.17r12064","article-title":"Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: a network meta-analysis","volume":"80","author":"Dobson","year":"2019","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/08039488.2022.2069858","article-title":"Comparative effectiveness of cognitive behavioral treatment, serotonin, and serotonin noradrenaline reuptake inhibitors for anxiety in children and adolescents: a network meta-analysis","volume":"77","author":"Arnard\u00f3ttir","year":"2023","journal-title":"Nord J Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2024.04.012_bib77","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jaac.2019.10.013","article-title":"Antidepressant tolerability in pediatric anxiety and obsessive-compulsive disorders: a bayesian hierarchical modeling meta-analysis","volume":"59","author":"Mills","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2024.04.012_bib78","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.psc.2024.04.012_bib79","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/JGP.0b013e31806841c8","article-title":"Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions","volume":"15","author":"Pinquart","year":"2007","journal-title":"Am J Geriatr Psychiatr"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.janxdis.2011.08.010","article-title":"Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis","volume":"26","author":"Gon\u00e7alves","year":"2012","journal-title":"J\u00a0Anxiety Disord"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib81","first-page":"157","article-title":"Anxiety in later life","volume":"15","author":"Aggarwal","year":"2017","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40501-017-0102-4","article-title":"Pharmacological management of anxiety disorders in the elderly","volume":"4","author":"Crocco","year":"2017","journal-title":"Curr Treat Options Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A\u00a0randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2024.04.012_bib84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-981-32-9705-0_19","article-title":"Current and novel psychopharmacological drugs for anxiety disorders","volume":"1191","author":"Bandelow","year":"2020","journal-title":"Anxiety disorders. Adv Exp Med Biol"},{"key":"10.1016\/j.psc.2024.04.012_bib86","article-title":"FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD","author":"Duerr","year":"2023","journal-title":"Psychiatr Times"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.psc.2024.04.012_bib88","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.psc.2024.04.012_bib89","doi-asserted-by":"crossref","first-page":"595584","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib90","doi-asserted-by":"crossref","first-page":"e100136","DOI":"10.1136\/gpsych-2019-100136","article-title":"Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches","volume":"32","author":"Bui","year":"2019","journal-title":"Gen Psychiatr"},{"key":"10.1016\/j.psc.2024.04.012_bib91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2017.02.047","article-title":"Characterization of 6-methoxyflavanone as a novel anxiolytic agent: A behavioral and pharmacokinetic approach","volume":"801","author":"Akbar","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib92","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"Mataix-Cols","year":"2017","journal-title":"JAMA Psychiatr"},{"issue":"9","key":"10.1016\/j.psc.2024.04.012_bib93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2024.04.012_bib94","author":"Ernst"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib95","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.psc.2024.04.012_bib96","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib97","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2024.04.012_bib98","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front Psychol"},{"issue":"11","key":"10.1016\/j.psc.2024.04.012_bib99","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.psc.2024.04.012_bib100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2015.06.004","article-title":"Oxytocin in general anxiety and social fear: a translational approach","volume":"79","author":"Neumann","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psc.2024.04.012_bib101","doi-asserted-by":"crossref","first-page":"146085","DOI":"10.1016\/j.brainres.2018.12.036","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy","volume":"1731","author":"Summers","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.psc.2024.04.012_bib102","article-title":"Vistagen announces positive top-line results from phase 3 PALISADE-2 trial of fasedienol (ph94b) nasal spray in social anxiety disorder","year":"2023","journal-title":"Vistagen"},{"key":"10.1016\/j.psc.2024.04.012_bib103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cpr.2018.06.005","article-title":"Estrogen, progesterone, and the menstrual cycle: A systematic review of fear learning, intrusive memories, and PTSD","volume":"66","author":"Garcia","year":"2018","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib104","first-page":"28","article-title":"The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress","volume":"4","author":"Liu","year":"2012","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"11","key":"10.1016\/j.psc.2024.04.012_bib105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","article-title":"Angiotensin type 1 receptor inhibition enhances the extinction of fear memory","volume":"75","author":"Marvar","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psc.2024.04.012_bib106","first-page":"CD003383","article-title":"Kava extract for treating anxiety","volume":"1","author":"Pittler","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib107","first-page":"147+","article-title":"Kava in the treatment of anxiety: a Cochrane review","volume":"18","author":"Pittler","year":"2006","journal-title":"Aust J Med Herbal"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004850-200609000-00001","article-title":"Kava in generalized anxiety disorder: three placebo-controlled trials","volume":"21","author":"Connor","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2024.04.012_bib109","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ptr.6033","article-title":"Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance","volume":"32","author":"Yeung","year":"2018","journal-title":"Phytother Res"},{"key":"10.1016\/j.psc.2024.04.012_bib110","series-title":"Evidence-based herbal and nutritional treatments for anxiety in psychiatric disorders","first-page":"11","article-title":"Herbal anxiolytics with sedative actions","author":"Sarris","year":"2016"},{"issue":"1","key":"10.1016\/j.psc.2024.04.012_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ptr.5940","article-title":"GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence","volume":"32","author":"Savage","year":"2018","journal-title":"Phytother Res"},{"issue":"2","key":"10.1016\/j.psc.2024.04.012_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition","volume":"26","author":"de la Torre","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.psc.2024.04.012_bib113","author":"Hwang"},{"issue":"10","key":"10.1016\/j.psc.2024.04.012_bib114","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.psc.2024.04.012_bib115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-Assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.psc.2024.04.012_bib116","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"issue":"12","key":"10.1016\/j.psc.2024.04.012_bib117","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"issue":"7","key":"10.1016\/j.psc.2024.04.012_bib118","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J\u00a0Nerv Ment Dis"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T21:44:34Z","timestamp":1730756674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X24000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0193953X24000340"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2024.04.012","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Anxiety Disorders","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}